TLR-2 agonist Pam3CSK4 has no therapeutic effect on visceral leishmaniasis in BALB/c mice and may enhance the pathogenesis of the disease

• Published in: Immunobiology (1979) Vol. 228; no. 5; p. 152725
• Main Authors: Liao, Xuechun, He, Jinlei, Wang, Ruanyan, Zhang, Jianhui, Wei, Shulan, Xiao, Yuying, Zhou, Qi, Zheng, Xiaoting, Zhu, Zheying, Zheng, Zhiwan, Li, Jiao, Zeng, Zheng, Chen, Dali, Chen, Jianping
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier GmbH 01.09.2023
• Subjects: Leishmania; Pam3CSK4; RNA-seq; TLR-2 agonist; Pam3CSK4; RNA-seq; TLR-2 agonist; Leishmania
• ISSN: 0171-2985; 1878-3279
• DOI: 10.1016/j.imbio.2023.152725

[Display omitted] •TLR-2 agonist Pam3CSK4 had no therapeutic effect on VL in BALB/c mice.•Pam3CSK4 may enhance the pathogenesis of the L. donovani infection in BALB/c mice.•Circadian rhythm may have important regulatory effect on host-Leishmania interaction. Most of the existing Leishmania-related research about TLR-2 agonists was focusing on their role as adjuvants in the vaccine, few studied its therapeutic effect. This paper aims to explore the therapeutic effect of TLR-2 agonist Pam3CSK4 on Leishmania-infected mice and the underlying immune molecular mechanisms. In L. donovani-infected BALB/c mice, one group was treated with Pam3CSK4 after infection and the other group was not treated. Normal uninfected mice treated with Pam3CSK4 or untreated were used as controls. Parasite load, hepatic pathology and serum antibodies were detected to assess the severity of the infection. The expression of immune-related genes, spleen lymphocyte subsets and liver RNA-seq were employed to reveal possible molecular mechanisms. The results showed that the liver and spleen parasite load of infected mice in Pam3CSK4 treated and untreated groups had no statistical difference, indicating Pam3CSK4 might have no therapeutic effect on visceral leishmaniasis. Infected mice treated with Pam3CSK4 possessed more hepatic inflammation focus, lower IgG and IgG2a antibody titers, and a lower proportion of spleen CD3+CD4+ T cells. Transcriptome analysis revealed that Th1/Th2 differentiation, NK cells, Th17 cell, complement system and calcium signaling pathways were down-regulated post-treatment of Pam3CSK4. In this study, TLR-2 agonist Pam3CSK4 showed no therapeutic effect on visceral leishmaniasis in BALB/c mice and might enhance the pathogenesis of the disease possibly due to the down-regulation of several immune-related pathways, which can improve our understanding of the role of TLR-2 in both treatment and vaccine development.